Health Care Reform's Impact Reflected In Pharma's Q1 Results
President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years
You may also be interested in...
Amgen says health care reform will trim its sails, but it's not much compared to the blow it took from the ESA safety problems.
Abbott adjusted its previous 2010 earnings per share guidance by $0.07 to range from $4.13 to $4.18.
Novartis sees no need to change its 2010 guidance based on health care reform and maintains its forecast for mid-single-digit growth.